As for this invention formula (i): (In formula, R1, - (CRR) n aryl, - (CRR) n hetero aryl, - (CRR) n O aryl or - (CRR) is n O hetero aryl or, (here, the aryl or hetero aryl basis is non substitution, or from group which low-grade alkyl or the non substitution or substitution phenyl which are substituted or halogen, low-grade alkyl and the low-grade alkoxy, by halogen (here, as for substitution of phenyl group it is possible to be low-grade alkyl or halogen,) consists of it is selected, it is substituted by 1 or 2 substituents,), or - (CRR) The n 2 benzo [1.3] it is jiokisoriru R/RHA becoming independent mutually, hydrogen, it is low-grade alkyl, or or the carbon atom which those have connected and it becomes simultaneous, it is shikuroarukiru R2 /R3 becoming independent mutually, hydrogen, being low-grade alkyl, phenyl or shikuroarukiru, or to be possible or the N atom which those have connected and becoming simultaneous, to form the saturation complex ring of 5 or 6 members n, 0 or 1 is) chemical compound, and that regards appropriate acid attaching salting pharmacy. This invention individual diastereoisomer and enantiomer of the chemical compound formula (i) and includes all stereoisomer forms which include that racemic and the non racemic mixture. As for this chemical compound, insecurity, the melancholia and bipolar obstacle, the parkinsons disease, the integrated malfunction symptom and it was discovered that it is selective arosuteritsukupojiteibumojiyureta of the human NK 3 receptor for painfully disposal.本発明は式(I):(式中、R1は、-(CRR’)n-アリール、-(CRR’)n-ヘテロアリール、-(CRR’)n-O-アリール若しくは-(CRR’)n-O-ヘテロアリールであるか(ここで、アリール又はヘテロアリール基は非置換であるか、あるいはハロゲン、低級アルキル、低級アルコキシ、ハロゲンにより置換されている低級アルキル、又は非置換若しくは置換フェニル(ここで、フェニル基の置換は低級アルキル又はハロゲンであってよい)からなる群より選択される、1若しくは2個の置換基により置換されている)、あるいは-(CRR’)n-2-ベンゾ[1.3]ジオキソリルであり;R/R’は互いに独立して、水素、低級アルキルであるか、あるいはそれらが結合している炭素原子と一緒になって、シクロアルキル基であり;R2/R3は互いに独立して水素、低級アルキル、フェニル又はシクロアルキルであるか、あるいはそれらが結合しているN-原子と一緒になって、5若しくは6員の飽和複素環を形成してよく;nは、0又は1である)の化合物、及びその薬
